دورية أكاديمية
أعرض في EDS

WHO Critical Priority Escherichia coli as One Health Challenge for a Post-Pandemic Scenario: Genomic Surveillance and Analysis of Current Trends in Brazil.

التفاصيل البيبلوغرافية
العنوان: WHO Critical Priority Escherichia coli as One Health Challenge for a Post-Pandemic Scenario: Genomic Surveillance and Analysis of Current Trends in Brazil.
المؤلفون: Fuga B; Department of Microbiology, Instituto de Ciências Biomédicas, University of São Paulo, São Paulo, Brazil.; Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.; One Health Brazilian Resistance Project (OneBR), São Paulo, Brazil., Sellera FP; One Health Brazilian Resistance Project (OneBR), São Paulo, Brazil.; Department of Internal Medicine, School of Veterinary Medicine and Animal Science, University of São Paulo, São Paulo, Brazil.; School of Veterinary Medicine, Metropolitan University of Santos, Santos, Brazil., Cerdeira L; Department of Microbiology, Instituto de Ciências Biomédicas, University of São Paulo, São Paulo, Brazil.; Department of Infectious Diseases, Central Clinical School, Monash Universitygrid.1002.3, Melbourne, Australia.; Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK., Esposito F; Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.; One Health Brazilian Resistance Project (OneBR), São Paulo, Brazil., Cardoso B; Department of Microbiology, Instituto de Ciências Biomédicas, University of São Paulo, São Paulo, Brazil.; One Health Brazilian Resistance Project (OneBR), São Paulo, Brazil., Fontana H; Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.; One Health Brazilian Resistance Project (OneBR), São Paulo, Brazil., Moura Q; Department of Microbiology, Instituto de Ciências Biomédicas, University of São Paulo, São Paulo, Brazil.; One Health Brazilian Resistance Project (OneBR), São Paulo, Brazil.; Faculty of Health Sciences, Federal University of Grande Dourados, Dourados, Mato Grosso do Sul, Brazil., Cardenas-Arias A; Department of Microbiology, Instituto de Ciências Biomédicas, University of São Paulo, São Paulo, Brazil.; One Health Brazilian Resistance Project (OneBR), São Paulo, Brazil., Sano E; Department of Microbiology, Instituto de Ciências Biomédicas, University of São Paulo, São Paulo, Brazil.; One Health Brazilian Resistance Project (OneBR), São Paulo, Brazil., Ribas RM; Laboratory of Molecular Microbiology, Institute of Biomedical Sciences, Federal University of Uberlândia, Uberlândia, Brazil., Carvalho AC; Clinical Laboratory, Federal University of Paraiba, João Pessoa, Paraíba, Brazil., Tognim MCB; School of Pharmacy, State University of Maringá, Maringá, Brazil., de Morais MMC; Institute of Biological Sciences, University of Pernambuco, Recife, Brazil., Quaresma AJPG; Laboratory of Special Pathogen Infections, Bacteriology and Mycology, Evandro Chagas Institute, Ananindeua, Brazil., Santana ÂP; Faculty of Agronomy and Veterinary Medicine, University of Brasília, Brasília, Brazil., Reis JN; Faculty of Pharmacy, Federal University of Bahiagrid.8399.b, Salvador, Brazil., Pilonetto M; Central Laboratory of the State of Paraná-LACEN, São Jose dos Pinhais, Brazil., Vespero EC; Microbiology Laboratory of the University Hospital of Londrina, State University of Londrina, Lonrina, Brazil., Bonelli RR; Medical Microbiology Research Laboratory, Paulo de Góes Institute of Microbiology, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil., Cerqueira AMF; Laboratory of Enteropathogens, Veterinary and Food Microbiology, Biomedical Institute, Fluminense Federal University, Niterói, Brazil., Sincero TCM; Laboratory of Applied Molecular Microbiology, Department of Clinical Analysis, Federal University of Santa Catarina, Florianópolis, Brazil., Lincopan N; Department of Microbiology, Instituto de Ciências Biomédicas, University of São Paulo, São Paulo, Brazil.; Department of Clinical Analysis, Faculty of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil.; One Health Brazilian Resistance Project (OneBR), São Paulo, Brazil.
المصدر: Microbiology spectrum [Microbiol Spectr] 2022 Apr 27; Vol. 10 (2), pp. e0125621. Date of Electronic Publication: 2022 Mar 02.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: ASM Press Country of Publication: United States NLM ID: 101634614 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2165-0497 (Electronic) Linking ISSN: 21650497 NLM ISO Abbreviation: Microbiol Spectr Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Washington, DC : ASM Press, 2013-
مواضيع طبية MeSH: Escherichia coli Infections*/epidemiology , One Health*, Animals ; Anti-Bacterial Agents/pharmacology ; Brazil/epidemiology ; Carbapenems/pharmacology ; Colistin ; Commerce ; Drug Resistance, Multiple, Bacterial/genetics ; Escherichia coli ; Genomics ; Internationality ; Microbial Sensitivity Tests ; Pandemics ; World Health Organization ; beta-Lactamases/genetics
مستخلص: The dissemination of carbapenem-resistant and third generation cephalosporin-resistant pathogens is a critical issue that is no longer restricted to hospital settings. The rapid spread of critical priority pathogens in Brazil is notably worrying, considering its continental dimension, the diversity of international trade, livestock production, and human travel. We conducted a nationwide genomic investigation under a One Health perspective that included Escherichia coli strains isolated from humans and nonhuman sources, over 45 years (1974-2019). One hundred sixty-seven genomes were analyzed extracting clinically relevant information (i.e., resistome, virulome, mobilome, sequence types [STs], and phylogenomic). The endemic status of extended-spectrum β-lactamase (ESBL)-positive strains carrying a wide diversity of bla CTX-M variants, and the growing number of colistin-resistant isolates carrying mcr -type genes was associated with the successful expansion of international ST10, ST38, ST115, ST131, ST354, ST410, ST648, ST517, and ST711 clones; phylogenetically related and shared between human and nonhuman hosts, and polluted aquatic environments. Otherwise, carbapenem-resistant ST48, ST90, ST155, ST167, ST224, ST349, ST457, ST648, ST707, ST744, ST774, and ST2509 clones from human host harbored bla KPC-2 and bla NDM-1 genes. A broad resistome to other clinically relevant antibiotics, hazardous heavy metals, disinfectants, and pesticides was further predicted. Wide virulome associated with invasion/adherence, exotoxin and siderophore production was related to phylogroup B2. The convergence of wide resistome and virulome has contributed to the persistence and rapid spread of international high-risk clones of critical priority E. coli at the human-animal-environmental interface, which must be considered a One Health challenge for a post-pandemic scenario. IMPORTANCE A One Health approach for antimicrobial resistance must integrate whole-genome sequencing surveillance data of critical priority pathogens from human, animal and environmental sources to track hot spots and routes of transmission and developing effective prevention and control strategies. As part of the Grand Challenges Explorations: New Approaches to Characterize the Global Burden of Antimicrobial Resistance Program, we present genomic data of WHO critical priority carbapenemase-resistant, ESBL-producing, and/or colistin-resistant Escherichia coli strains isolated from humans and nonhuman sources in Brazil, a country with continental proportions and high levels of antimicrobial resistance. The present study provided evidence of epidemiological and clinical interest, highlighting that the convergence of wide virulome and resistome has contributed to the persistence and rapid spread of international high-risk clones of E. coli at the human-animal-environmental interface, which must be considered a One Health threat that requires coordinated actions to reduce its incidence in humans and nonhuman hosts.
التعليقات: Comment in: Microbiol Spectr. 2022 Aug 31;10(4):e0150622. (PMID: 35762783)
References: J Clin Microbiol. 2014 Jan;52(1):139-46. (PMID: 24172157)
Sci Rep. 2021 Jul 19;11(1):14679. (PMID: 34282205)
J Antimicrob Chemother. 2012 Nov;67(11):2640-4. (PMID: 22782487)
Front Microbiol. 2019 Dec 05;10:2826. (PMID: 31866986)
Gut Pathog. 2019 Feb 21;11:10. (PMID: 30828388)
Antimicrob Agents Chemother. 2019 May 24;63(6):. (PMID: 30885899)
FEMS Microbiol Rev. 2016 Jul 1;40(4):437-463. (PMID: 28201713)
Int J Antimicrob Agents. 2016 Dec;48(6):598-606. (PMID: 27836380)
Sci Rep. 2017 Jul 19;7(1):5917. (PMID: 28725045)
mSphere. 2018 Jul 18;3(4):. (PMID: 30021879)
Sci Rep. 2018 Jul 6;8(1):10291. (PMID: 29980699)
Am J Infect Control. 2020 Sep;48(9):1129-1130. (PMID: 32603851)
J Hosp Infect. 2021 Jan;107:114-115. (PMID: 33217492)
Diagn Microbiol Infect Dis. 2017 May;88(1):69-74. (PMID: 28214224)
Int J Infect Dis. 2011 Feb;15(2):e136-9. (PMID: 21130676)
Front Microbiol. 2017 Aug 31;8:1650. (PMID: 28912764)
Microorganisms. 2020 Jun 11;8(6):. (PMID: 32545206)
PLoS One. 2020 May 29;15(5):e0227725. (PMID: 32469888)
Bioinformatics. 2015 Nov 15;31(22):3691-3. (PMID: 26198102)
Clin Infect Dis. 2018 Nov 13;67(suppl_2):S217-S224. (PMID: 30423047)
Braz J Microbiol. 2016 Dec;47 Suppl 1:31-37. (PMID: 27825605)
Nat Commun. 2018 Mar 21;9(1):1179. (PMID: 29563494)
Antibiotics (Basel). 2020 Jan 31;9(2):. (PMID: 32023977)
Sci Rep. 2016 Apr 14;6:24099. (PMID: 27076285)
Essays Biochem. 2017 Mar 3;61(1):11-21. (PMID: 28258226)
J Antimicrob Chemother. 2021 Apr 13;76(5):1299-1302. (PMID: 33417711)
Nat Microbiol. 2019 Sep;4(9):1432-1442. (PMID: 31439928)
Front Microbiol. 2012 Feb 02;3:24. (PMID: 22347217)
Microb Genom. 2016 Apr 29;2(4):e000056. (PMID: 28348851)
Infect Genet Evol. 2018 Dec;66:48-51. (PMID: 30227226)
Clin Microbiol Rev. 2015 Jul;28(3):565-91. (PMID: 25926236)
Nat Rev Microbiol. 2021 Jan;19(1):37-54. (PMID: 32826992)
Front Microbiol. 2015 Aug 05;6:791. (PMID: 26300860)
MMWR Morb Mortal Wkly Rep. 2020 Dec 04;69(48):1827-1831. (PMID: 33270611)
Microbiol Res. 2021 Sep;250:126790. (PMID: 34098495)
Clin Microbiol Infect. 2012 Mar;18(3):268-81. (PMID: 21793988)
Mar Pollut Bull. 2020 Jan;150:110689. (PMID: 31733900)
Sci Rep. 2019 Nov 11;9(1):16457. (PMID: 31712587)
PLoS Comput Biol. 2017 Jun 8;13(6):e1005595. (PMID: 28594827)
Microb Genom. 2018 Jul;4(7):. (PMID: 29916797)
Toxins (Basel). 2018 Apr 10;10(4):. (PMID: 29642622)
Appl Environ Microbiol. 2020 Mar 18;86(7):. (PMID: 31953334)
mBio. 2019 Jan 22;10(1):. (PMID: 30670621)
Methods Mol Biol. 2020;2075:285-294. (PMID: 31584170)
Bioinformatics. 2019 Nov 1;35(21):4453-4455. (PMID: 31070718)
mBio. 2018 Aug 28;9(4):. (PMID: 30154256)
Future Microbiol. 2016;11(1):81-92. (PMID: 26674470)
Nucleic Acids Res. 2011 Jul;39(Web Server issue):W475-8. (PMID: 21470960)
Front Microbiol. 2021 Apr 01;12:626774. (PMID: 33868190)
Sci Rep. 2017 Aug 22;7(1):9141. (PMID: 28831073)
J Clin Microbiol. 2015 Aug;53(8):2410-26. (PMID: 25972421)
Front Microbiol. 2018 Feb 16;9:243. (PMID: 29503639)
Sci Rep. 2017 Nov 10;7(1):15364. (PMID: 29127343)
Microbiol Spectr. 2018 Mar;6(2):. (PMID: 29600770)
J Antimicrob Chemother. 2015;70(6):1639-49. (PMID: 25687644)
Front Microbiol. 2017 Oct 25;8:2094. (PMID: 29118748)
Int J Antimicrob Agents. 2021 Apr;57(4):106324. (PMID: 33746045)
Front Microbiol. 2017 Nov 10;8:2232. (PMID: 29176971)
Emerg Infect Dis. 2020 Aug;26(8):1951-1954. (PMID: 32687033)
J Hosp Infect. 2021 Apr;110:165-171. (PMID: 33561503)
Microbiol Spectr. 2016 Apr;4(2):. (PMID: 27227291)
PLoS One. 2015 Mar 10;10(3):e0117906. (PMID: 25756870)
FEMS Microbiol Rev. 2011 Sep;35(5):736-55. (PMID: 21303394)
mSystems. 2021 Feb 9;6(1):. (PMID: 33563779)
Future Microbiol. 2018 Jun 1;13:745-756. (PMID: 29870278)
Microb Drug Resist. 2021 Dec;27(12):1705-1725. (PMID: 34077290)
J Antimicrob Chemother. 2021 Aug 12;76(9):2225-2229. (PMID: 34109407)
Lancet Planet Health. 2018 Sep;2(9):e398-e405. (PMID: 30177008)
Zoonoses Public Health. 2021 May;68(3):226-238. (PMID: 33619864)
Lancet Infect Dis. 2018 Mar;18(3):318-327. (PMID: 29276051)
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2505-8. (PMID: 26824955)
PLoS One. 2017 Jun 8;12(6):e0178970. (PMID: 28594893)
Environ Sci Pollut Res Int. 2021 Oct;28(38):54147-54152. (PMID: 34389944)
Antimicrob Agents Chemother. 2020 Sep 21;64(10):. (PMID: 32747356)
Front Microbiol. 2021 Apr 09;12:659900. (PMID: 33897674)
Clin Infect Dis. 2011 May;52(9):1138-43. (PMID: 21467020)
J Antimicrob Chemother. 2017 Apr 1;72(4):1255-1256. (PMID: 28031274)
Transbound Emerg Dis. 2021 Mar;68(2):258-266. (PMID: 32544292)
Microb Genom. 2016 Nov 30;2(11):e000093. (PMID: 28348833)
Bioinformatics. 2014 Jul 15;30(14):2068-9. (PMID: 24642063)
BMC Bioinformatics. 2009 Dec 15;10:421. (PMID: 20003500)
J Clin Microbiol. 2012 Apr;50(4):1355-61. (PMID: 22238442)
Antimicrob Agents Chemother. 2017 Apr 24;61(5):. (PMID: 28193665)
J Glob Antimicrob Resist. 2018 Dec;15:252-253. (PMID: 30404045)
فهرسة مساهمة: Keywords: ESBL; Enterobacterales; MCR; One Health; South America; carbapenemases; carbapenems; colistin; genomic surveillance; high-risk clones; multidrug resistance; resistome; virulome
المشرفين على المادة: 0 (Anti-Bacterial Agents)
0 (Carbapenems)
EC 3.5.2.6 (beta-Lactamases)
Z67X93HJG1 (Colistin)
تواريخ الأحداث: Date Created: 20220302 Date Completed: 20220429 Latest Revision: 20221012
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC8941879
DOI: 10.1128/spectrum.01256-21
PMID: 35234515
قاعدة البيانات: MEDLINE
الوصف
تدمد:2165-0497
DOI:10.1128/spectrum.01256-21